Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients

Abstract MicroRNAs (miRNAs) are noncoding RNAs that contribute to gene expression modulation by regulating important cellular pathways. In this study, we used small RNA sequencing to identify a series of circulating miRNAs in blood samples taken from Friedreich’s ataxia patients. We were thus able t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Seco-Cervera, D. González-Rodríguez, J. S. Ibáñez-Cabellos, L. Peiró-Chova, P. González-Cabo, E. García-López, J. J. Vílchez, I. Sanz-Gallego, F. V. Pallardó, J. L. García-Giménez
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e6d232ffeb4b41f99d56aff3acabb26b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6d232ffeb4b41f99d56aff3acabb26b
record_format	dspace
spelling	oai:doaj.org-article:e6d232ffeb4b41f99d56aff3acabb26b2021-12-02T12:32:03ZCirculating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients10.1038/s41598-017-04996-92045-2322https://doaj.org/article/e6d232ffeb4b41f99d56aff3acabb26b2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-04996-9https://doaj.org/toc/2045-2322Abstract MicroRNAs (miRNAs) are noncoding RNAs that contribute to gene expression modulation by regulating important cellular pathways. In this study, we used small RNA sequencing to identify a series of circulating miRNAs in blood samples taken from Friedreich’s ataxia patients. We were thus able to develop a miRNA biomarker signature to differentiate Friedreich’s ataxia (FRDA) patients from healthy people. Most research on FDRA has focused on understanding the role of frataxin in the mitochondria, and a whole molecular view of pathological pathways underlying FRDA therefore remains to be elucidated. We found seven differentially expressed miRNAs, and we propose that these miRNAs represent key mechanisms in the modulation of several signalling pathways that regulate the physiopathology of FRDA. If this is the case, miRNAs can be used to characterize phenotypic variation in FRDA and stratify patients’ risk of cardiomyopathy. In this study, we identify miR-323-3p as a candidate marker for phenotypic differentiation in FRDA patients suffering from cardiomyopathy. We propose the use of dynamic miRNAs as biomarkers for phenotypic characterization and prognosis of FRDA.M. Seco-CerveraD. González-RodríguezJ. S. Ibáñez-CabellosL. Peiró-ChovaP. González-CaboE. García-LópezJ. J. VílchezI. Sanz-GallegoF. V. PallardóJ. L. García-GiménezNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q M. Seco-Cervera D. González-Rodríguez J. S. Ibáñez-Cabellos L. Peiró-Chova P. González-Cabo E. García-López J. J. Vílchez I. Sanz-Gallego F. V. Pallardó J. L. García-Giménez Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
description	Abstract MicroRNAs (miRNAs) are noncoding RNAs that contribute to gene expression modulation by regulating important cellular pathways. In this study, we used small RNA sequencing to identify a series of circulating miRNAs in blood samples taken from Friedreich’s ataxia patients. We were thus able to develop a miRNA biomarker signature to differentiate Friedreich’s ataxia (FRDA) patients from healthy people. Most research on FDRA has focused on understanding the role of frataxin in the mitochondria, and a whole molecular view of pathological pathways underlying FRDA therefore remains to be elucidated. We found seven differentially expressed miRNAs, and we propose that these miRNAs represent key mechanisms in the modulation of several signalling pathways that regulate the physiopathology of FRDA. If this is the case, miRNAs can be used to characterize phenotypic variation in FRDA and stratify patients’ risk of cardiomyopathy. In this study, we identify miR-323-3p as a candidate marker for phenotypic differentiation in FRDA patients suffering from cardiomyopathy. We propose the use of dynamic miRNAs as biomarkers for phenotypic characterization and prognosis of FRDA.
format	article
author	M. Seco-Cervera D. González-Rodríguez J. S. Ibáñez-Cabellos L. Peiró-Chova P. González-Cabo E. García-López J. J. Vílchez I. Sanz-Gallego F. V. Pallardó J. L. García-Giménez
author_facet	M. Seco-Cervera D. González-Rodríguez J. S. Ibáñez-Cabellos L. Peiró-Chova P. González-Cabo E. García-López J. J. Vílchez I. Sanz-Gallego F. V. Pallardó J. L. García-Giménez
author_sort	M. Seco-Cervera
title	Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
title_short	Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
title_full	Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
title_fullStr	Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
title_full_unstemmed	Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients
title_sort	circulating mir-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in friedreich’s ataxia patients
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e6d232ffeb4b41f99d56aff3acabb26b
work_keys_str_mv	AT msecocervera circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT dgonzalezrodriguez circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT jsibanezcabellos circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT lpeirochova circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT pgonzalezcabo circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT egarcialopez circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT jjvilchez circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT isanzgallego circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT fvpallardo circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients AT jlgarciagimenez circulatingmir3233pisabiomarkerforcardiomyopathyandanindicatorofphenotypicvariabilityinfriedreichsataxiapatients
_version_	1718394189738147840

Circulating miR-323-3p is a biomarker for cardiomyopathy and an indicator of phenotypic variability in Friedreich’s ataxia patients

Ejemplares similares